MedTrace Logo

Intravitreal Avastin in Proliferative Retinopathies

NCT00564148 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-07-22

No results posted yet for this study

Summary

The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes

Conditions

  • Retinal Neovascularization

Interventions

DRUG

Avastin

2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively

Sponsors & Collaborators

  • Ophthalmological Association Edelweiss

    lead OTHER

Principal Investigators

  • NARCISA IANOPOL, researcher · Ophthalmological Association Edelweiss

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • Romania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564148 on ClinicalTrials.gov